Plain-English translation of NCT07629960 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new medication called , which is designed to target cancers that have a specific type of KRAS gene mutation. Researchers are trying to find the safest and most effective dose of this treatment, and to see how well it works against advanced pancreatic cancer, lung cancer, or colorectal cancer. The study will start by giving people gradually increasing doses to understand how their body handles the medication, then move to testing it in larger groups of patients with each cancer type.
Many people with these types of advanced cancer have KRAS mutations, which drive tumor growth and make cancers harder to treat. This medication is designed specifically to target this mutation, and researchers hope it may offer a new treatment option for patients whose tumors have these genetic changes.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth once daily as a tablet. The study starts with a dose-escalation phase where doses are gradually increased to find the safest level, followed by a dose-enrichment phase with more patients at selected doses, and finally a dose-expansion phase focused on your specific cancer type. Throughout the trial, you will have regular visits for blood tests, imaging scans, and check-ins to monitor how you're responding and any side effects you experience.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States